to host cells and potentiating its signaling activity. In certain disease states, such as obesity, the overproduction of this protein has been a reliable biomarker of chronic inflammation. Here, we describe a symbiosis-induced invertebrate LBP whose tertiary structure and LPSbinding characteristics are similar to those of mammalian LBPs; however, the primary structure of this distantly related squid protein (EsLBP1) differs in key residues previously believed to be essential for LPS binding, suggesting that an alternative strategy exists. Surprisingly, symbiotic expression of eslbp1 is induced by peptidoglycan derivatives, not LPS, a pattern converse to that of RegIII␥, an important mammalian immunity protein that binds peptidoglycan but whose gene expression is induced by LPS. Finally, EsLBP1 occurs along the apical surfaces of all the host's epithelia, suggesting that it was recruited from a general defensive role to one that mediates specific interactions with its symbiont. 
their luminescence for use in host behaviors. MAMP-induced morphogenetic programs include the apoptotic loss of the ciliated epithelium that potentiates initial colonization, recruitment of macrophagelike blood cells into the organ, and the transformation of the biochemical environment where the symbionts take up residence in host tissues (for reviews, see references 3 and 4). The luminescence from the V. fischeri monoculture in the light organ allows E. scolopes to match ambient light and thereby disguise its shadow (5) . Subsequent studies in mammals have demonstrated that MAMPs also drive development, such as immune system maturation, in complex host-microbial associations, including in the mammalian gut (2) . This study uses the squid-vibrio model to provide experimental evidence for the role of lipopolysaccharidebinding protein (LBP), a member of the LBP/BPI (bactericidal/ permeability-increasing protein) protein family, as a key player in host responses to symbiont LPS.
As MAMP recognition proteins, mammalian LBP and BPI are closely related, structurally similar proteins that serve complementary roles in innate immunity. LBP relays LPS to host cells, whereas BPI acts as a bactericidal/LPS-neutralizing effector molecule to help clear infection and resolve infection-induced inflammation (6, 7) . LBP is present in plasma and tissue fluids, and recent reports have determined that LBP and BPI are expressed in the gut and other epithelia, where they likely mediate responses to the interfacing microbiota (8, 9) . During an inflammatory response, the constitutively present levels of LBP are sufficient to catalyze extraction and delivery of individual LPS molecules to CD14 and MD-2/TLR4 to induce potent proinflammatory responses (10) (11) (12) (13) . LBP levels can increase up to 100-fold during acute-phase reactions following the initial inflammatory responses, promoting, along with BPI, noninflammatory clearance of LPS and eventual resolution of LPS-triggered inflammation (11, 14, 15) . Unlike BPI, LBP binding to Gram-negative bacteria (e.g., Escherichia coli) does not produce lethal or sublethal alterations of the bacteria (16) .
Despite differences in activity between mammalian LBP and BPI, the structural organization conferring function is generally similar. Thus, the N-terminal domain of each protein binds LPS, whether presented in the form of intact Gram-negative bacteria (16, 17) , shed outer membrane blebs, or aggregates of purified LPS (18) (19) (20) . The C-terminal domain of both LBP and BPI is responsible for delivery of the bound LPS-containing material to host cells (18, 20, 21) . Conserved, positively charged residues near the N-terminal tip of both mammalian LBP and BPI are likely important in initial electrostatic interactions with typically polyanionic LPS (22) (23) (24) (25) . The net cationicity is greater in BPI than in LBP in both the charged N-terminal tip and across the molecule; the isoelectric point (pI) of LBP is near neutral, whereas the BPI pI is~10. This difference in charge likely accounts for the higher LPS-and bacterial-binding affinity of BPI and the distinct effects that LBP and BPI produce on LPS-rich interfaces, including bacterial outer membranes (21, 26) . BPI causes bacterial sublethal and lethal injury, whereas LBP promotes extraction of individual LPS molecules by CD14 at substoichiometric concentrations (12, 19) .
Although the gene duplication giving rise to mammalian LBP and BPI is believed to have occurred after the radiation of the mammals (27) , related proteins have been reported in several invertebrate groups (28, 29) . While a given invertebrate species may have multiple LBP/BPI gene isoforms, an LBP/BPI dichotomy has not been well characterized outside the mammals. Sequence analysis across the animal kingdom shows that these proteins are relatively quickly evolving, with~21% identity between E. scolopes LBP1 (EsLBP1) and mammalian LBP/BPI proteins, indicating 1% change in the amino acid sequence every 7 million years. A comparative analysis of structure and function across these deep divergences that have occurred over more than 500 million years offers the opportunity to define biochemical features that are essential for function of these molecules, as well as to explore how evolutionary tinkering can give rise to diversity of function.
Full-length transcripts of four members of the LBP/BPI protein family have been identified in E. scolopes (28, 30) . One of these proteins, EsLBP1 (previously called EsLBP [31] ), is of particular interest as a candidate for responding to symbiont LPS during development. The pI of EsLBP1 is near neutral, suggesting that it functions similarly to mammalian LBPs, i.e., presenting LPS as a signal molecule. In addition, the gene encoding EsLBP1 increases in expression at 18 h following the onset of host-symbiont interaction, a time when morphogenesis is being signaled by MAMPs (31) . In the present study, to provide insight into the possible role of an LBP in inducing an animal developmental program, we sought to characterize the biochemical properties of EsLBP1, comparing them to those of mammalian LBP, and to examine the timing and location of EsLBP1 gene expression and protein production through the early trajectory of host development.
RESULTS

Structural comparison of LPS-binding domain of mammalian
LBP and BPI to corresponding region of EsLBP1. We focused on the LPS-binding N-terminal domain of human LBP/BPI (hLBP/ hBPI) proteins for comparison with EsLBP1 by primary sequence alignment (Fig. 1A) . Overall, the degree of conservation with human LBP/BPI proteins is limited; EsLBP1 is 23.6% identical to hBPI and 25.7% identical to hLBP within this region. In contrast to the extensive differences in overall primary structure, the polycationic region of mammalian BPI and LBP most strongly implicated in LPS binding (residues 86 to 102) (22) (23) (24) also represents the most cationic local region of EsLBP1 (Fig. 1A) . The sequence alignment of human and squid proteins predicts that the disulfide bond of the mammalian LBP/BPI family within the N-terminal domain (32) is conserved in EsLBP1 (Fig. 1A) . The tertiary structure of EsLBP1, as derived by SWISS-MODEL, is most similar to the 2.40-Å structure of human BPI (SMTL accession number 1BP1.1.A) (22) . The QMEAN4 score, a protein model quality measure based on scoring functions like torsion and solvation that are related to model geometry (33) , is Ϫ5.63 (Fig. 1B) . Thus, the overall model quality is low, i.e., confidence that the threedimensional (3-D) structure of BPI can predict that of EsLBP1 is limited. However, it should be noted that the model quality varies greatly by region (Fig. 1B) , conforming well in the extended protein regions that define the unique boomeranglike configuration of mammalian LBP and BPI (22, 34) but deviating greatly in regions in both the N-and C-terminal domains that impart interactive properties specific to LBP or BPI. For example, the highest net concentration of positive charge present in mammalian BPI and LBP, at the tip region of the N-terminal domain ( Fig. 1D and E), is also manifest in EsLBP1 (Fig. 1C) but in an area of high divergence from the template. The residues predicted by ClustalW2 alignment to be involved in the conserved disulfide bond (Fig. 1A) are in an area of relatively good fit to the BPI template and in close proximity to each other, as in human BPI ( Fig. 1F and G (Fig. 2B) .
As mammalian LBP has a role in binding pneumococcal cell wall fragments (36), we sought to determine whether EsLBP1 binds the peptidoglycan monomer, TCT. Additionally, human LBP reacts with monomeric endotoxin:CD14 complexes to form supramolecular complexes containing LBP, endotoxin, and CD14 (J. P. Weiss unpublished data). We adapted the LOS/LPS capture assay described above to measure binding to [ 3 H]TCT and to [ 3 H]LOS:human CD14 complexes, but in neither case was EsLBP1-dependent cocapture observed ( Fig. 2C and D) . Thus, we found no evidence for EsLBP1 binding of TCT or LOS:CD14 complexes.
EsLBP1 does not kill Escherichia coli. The pI of EsLBP1 suggests that it more likely functions like LBP and not BPI. To test this hypothesis more directly, we assayed the effects of EsLBP1 and, for comparison, recombinant human LBP and BPI-21 (the LPSbinding and bactericidal N-terminal M r 21,000 fragment of human BPI [37] ) on the viability of E. coli. As shown previously (16, 17) , BPI but not LBP produced killing of E. coli, as manifested by reduced CFU (Fig. 3) . At the same protein concentration tested, EsLBP1 had no effect on bacterial viability, resembling mammalian LBP.
eslbp1 transcript expression is induced by symbiosis and TCT but not by the binding partner, LPS. Previous microarray results (31) showed that EsLBP1 is upregulated at 18 h following colonization of E. scolopes by V. fischeri, i.e., following the first full colonization of host crypts. Here, we used quantitative reverse transcriptase PCR (qRT-PCR) with gene-specific primer sets (see Table S1 in the supplemental material) to establish the time course of eslbp1 expression over the trajectory of early development. We also investigated the role of symbiont MAMPs in the induction of eslbp1. A reproducible, significant,~3-fold difference in eslbp1 expression between aposymbiotic and symbiotic light organs was first observed at 12 h postinoculation; the degree of upregulation in symbiotic over aposymbiotic light organs at 24 h varied but was typically greater than 20-fold ( Fig. 4A ). Lipid A, the LPS derivative involved in symbiont-induced development, from either V. fischeri or E. coli was used at 10 ng/ml, a level that optimally induces host cell phenotypes, but it did not induce changes in eslbp1 expression. However, TCT added at 1 M was shown to increase eslbp1~11-fold over the background level; the TCT effect was not further amplified by the addition of lipid A ( Fig. 4B and C) . eslbp1 transcripts localize to light organ tissues interfacing with V. fischeri. Using hybridization chain reaction-fluorescent in situ hybridization (HCR-FISH), we localized the expression of eslbp1 within the light organ to determine whether the gene is expressed in proximity to V. fischeri and to ascertain the steps of the establishment of symbiosis in which EsLBP1 may play a role. We evaluated the locations of transcripts in light organs at 24 h postinoculation using gene-specific probes for eslbp1, for hsp90 (as a counterstain for E. scolopes tissue), and for V. fischeri 16S ribosomal subunit (to label the symbionts) (see Table S2 in the supplemental material). eslbp1 transcript signals in symbiotic light organs were elevated relative to the levels in nonsymbiotic light organs throughout the epithelial surfaces closely associated with V. fischeri, including the pores, ducts, and crypts of the organ (Fig. 5) .
EsLBP1 protein is present at epithelial surfaces that directly associate with bacteria and with the environment. We compared the data on the localization of eslbp1 transcripts and of protein.
Using chicken anti-EsLBP1 antibody, we confirmed and expanded upon previously reported EsLBP1 localization at 18 h postinoculation in symbiotic animals (31). EsLBP1 was highly abundant throughout the light organ (Fig. 6B ). The antibody crossreactivity was high in anterior-appendage epithelial cells, as well as the apical surfaces of pore and duct cells. EsLBP1 protein was also abundant in the extracellular crypt spaces of symbiotic light organs, the site of long-term colonization by V. fischeri (Fig. 6C) .
To determine whether EsLBP1 protein is specific to the light organ, we also analyzed other epithelial tissues of the squid that interact with environmental bacteria, including tentacles, gills, and eyes ( Fig. 6D to F) . We found that the protein is not exclusive to the light organ but is abundant along the apical surfaces of many or perhaps all epithelia but absent in deeper tissues, such as muscle. The signal was not seen in light organs or other tissues treated with preimmune serum (Fig. 6G) .
DISCUSSION
In this study, we provide evidence based on both functional assays and structural modeling that is consistent with EsLBP1 functioning as an LBP-like protein. Most notably, EsLBP1 binds Gramnegative bacterial LOS and LPS with nanomolar or higher avidity under in vitro conditions, i.e., when LPS/LOS is presented as part of supramolecular assemblies containing LPS-rich lipid-water interfaces, as in aggregates of purified LPS/LOS. eslbp1 gene expression is regulated by exposure to the peptidoglycan monomer TCT, which synergizes with LPS in the triggering of V. fischeri-induced morphogenesis of the host symbiotic tissues. The gene is expressed and the protein produced across the organ's epithelia-from the point where V. fischeri initially gathers, along the path of its migration, to where it takes up permanent residence in the crypts. The protein is also abundant along the apical surfaces of other epithelial tissues, where colonization by bacteria does not occur.
Although EsLBP1 has only~25% primary structure identity with mammalian LBPs in the N-terminal domain (Fig. 1A) and 21% overall, several key structural features likely important for LPS-related functions are predicted to be conserved. These fea- tures include (i) the localization of the most cationic region of these proteins within the predicted outer tip of the N-terminal domain of these proteins (Fig. 1C to E) , albeit with substitutions in some specific cationic residues that are conserved in mammalian LBP and BPI, (ii) the extended configuration of the holoproteins, possibly important for the coordinated binding of LPS-rich supramolecular assemblies by the N-terminal domain and delivery of LPS to specific host targets mediated by the C-terminal domain, and (iii) the presence of conserved cysteines (140 and 175) within the N-terminal domain that form a disulfide linkage necessary for protein stability and function (38) . Replacements of specific cationic residues conserved in mammalian LBP and BPI are common in proteins of this family in many nonmammalian vertebrates and invertebrates, including the Atlantic cod Gadus morhua and mollusks Crassostrea gigas (oyster) and Biomphalaria glabrata (snail) (28, 39, 40) , reinforcing the notion that the overall charge of the region is critical. Remarkably, the much lower avidity of mammalian LBP and BPI for F. tularensis LPS compared to their avidity for meningococcal LOS (35) is also manifest with EsLBP1 (Fig. 2B) . These data suggest similar determinants of LPS interaction with the mammalian and squid proteins. In addition, they are consistent with a key role of electrostatic interactions between cationic regions of the proteins and anionic moieties at or closely neighboring the lipid A region of most LPS/LOS species that are less prominent in F. tularensis LPS (41) . It is noteworthy that the quality of the 3-D model of EsLBP1 is strongest within the core of the boomerang-shaped structure that is unique to the LBP/BPI family (22, 34) . Regions of EsLBP1 that diverge from the human BPI 3-D structure template are generally at the periphery of the molecule. Divergence at the N terminus could reflect greater intrinsic mobility of the LPS-binding region to optimize interactions with diverse LPS-rich bacterial interfaces, and divergence at the C terminus may correspond to functional regions that have evolved to recognize different (e.g., host) targets. It is also noteworthy that the predicted structure of EsLBP1 within the C-terminal domain resembles that of mammalian LBP (34) more than that of BPI (22, 42) , lacking the A= helix present in BPI and instead forming a loop in this region that is displaced relative to the corresponding region of BPI (Fig. 1B) .
The regulation of lbp gene expression by TCT and not LPS was unexpected, given that in mammalian systems, LPS increases lbp expression (43, 44); we are not aware of experiments showing the effect of peptidoglycan treatment on mammalian lbp transcript or protein levels. Recent studies have indicated that LPS preparations are often contaminated with trace amounts of peptidoglycan, which can actually be the element that is active (45) . In light of the results in the squid system, a revisit of the MAMP induction of genes encoding mammalian LBP/BPI may be fruitful. Regulation of an LBP by TCT is of added interest, as it is the converse of the regulation of expression of a well-studied C-type lectin, RegIII␥. This protein is expressed in the intestinal epithelium of mice, binds peptidoglycan, and is preferentially bactericidal against Gram-positive bacteria (46, 47) . However, the expression of the gene encoding RegIII␥ is induced by the presence of Gramnegative bacteria or LPS (47, 48) .
Cross talk and synergy between MAMPs and their receptors have been observed elsewhere in mammalian systems. TCT and lipid A act synergistically in the case of nitric oxide synthase induction during Bordetella pertussis infection of hamster tracheal cells (49, 50) ; in this case, TCT and lipid A are thought to deliver their signal through parallel pathways. In contrast, a sequential priming effect of peptidoglycan on the LPS response has been noted in human blood; the administration of staphylococcal peptidoglycan increases the response to subsequent LPS treatment, apparently through upregulation of such factors as CD14 and Toll-like receptor 4 (TLR4) on monocytes (51). Our experimental results suggest a similar mechanistic relationship in the squid, wherein increased eslbp1 gene expression induced by TCT promotes developmental responses induced by LPS and thus results in the LPS-peptidoglycan synergy in squid-vibrio symbiosis that has been described (4). This synergy may be particularly important given the relatively low potency of the V. fischeri LPS (52), presumably related to its unusual acyl chain and O-antigen structure (53, 54) , which may serve to protect the host from endotoxicity. TCT's induction of eslbp1 is another example of peptidoglycan products from beneficial bacteria influencing host immune development. In mammals, the diverse effects attributed to the peptidoglycan of the microbiota include maturation of the gutassociated lymphoid tissues (reviewed in reference 55).
Although the irreversible signal for light organ morphogenesis is delivered by MAMP-host cell interactions in the crypt spaces, cell death does not occur in these epithelia. Instead, at~12 h, the MAMPS remotely trigger an irreversible program of cell death that results in a 4-to 5-day regression of the superficial ciliated epithelia, which are several cell layers away from the crypts (56) . eslbp1 is significantly upregulated at this 12-h time point (Fig. 4A) , and thus, its expression is plausibly timed to play a role in the transmission of this signal. Furthermore, the crypt epithelia have an abundance of this protein (Fig. 6C) , a finding reminiscent of the observation of LBP in the mucus of mouse intestines (9) .
Our studies of EsLBP1 show that it is not exclusively a light organ protein but, rather, is abundant in most if not all epithelia (Fig. 6D to F) . These data suggest that the light organ has recruited LBP as a protein to signal the presence of a mutualistic partner or control its population rather than to respond to a pathogen. The hypothesized signaling role for EsLBP1 is unproven but is supported by EsLBP1's structural and functional properties, which resemble mammalian LBP more closely than BPI. These features include its predicted near-neutral isoelectric point (28) and the absence of bactericidal activity (Fig. 3) , which are distinguishing features of mammalian LBP compared to BPI (12) .
In mammals, LBP can either promote LPS-triggered inflammation or blunt it by promoting noninflammatory clearance mechanisms (6, (11) (12) (13) (14) 57) . The former seems entirely CD14 dependent, whereas the latter is largely CD14 independent. No CD14 has been detected among E. scolopes transcripts, although transcripts with an MD-2-related lipid-recognition (ML) domain have been noted (30) . The inability of EsLBP1, unlike mammalian LBP, to interact with monomeric LOS:soluble CD14 complexes (Fig. 2D ) leaves open the possibility of an alternative target of EsLBP1-LPS complexes. In mammals, up to 100-fold increases in extracellular LBP levels can promote "silent uptake" of LPS rather than activation of inflammation (10, 11, 14) . Thus, future studies in the squid will also need to investigate whether induced increases in EsLBP1 levels also have more complex effects on the evolution of the symbiotic response and relationship.
The presence of multiple proteins in the LBP/BPI family in E. scolopes that are predicted to have various biochemical properties (28) raises the possibility that the squid, like mammals, expresses both LBP-like and BPI-like proteins whose expression and functions are differentiated in a way to best coordinate host responses to Gram-negative bacterial interaction, in this case leading to E. scolopes-Vibrio fischeri symbiosis. If so, this system would provide the first example outside mammals of the coexistence of both LBP-and BPI-like family members in a single species. Future studies of this family of lipid (LPS)-binding proteins during E. scolopes-V. fischeri symbiosis should advance the understanding of both the evolution and structure/function of the LBP/BPI family and its role in mutualism. LBP may also play important roles, as yet mostly unknown, in others of the innumerable beneficial animal-bacterial associations.
MATERIALS AND METHODS
Alignment of EsLBP1 with mammalian LBP and BPI. Human BPI (NCBI accession no. CAD99178.1), human LBP (AAB31143.1), and Es-LBP1 (JF514880.1) sequences were aligned using ClustalW2 (58, 59) . LBP/BPI family N-terminal domains were defined by SMART (60) . A 3-D model of EsLBP1 was formed with SWISS-MODEL (61) (62) (63) (64) ; the model with the best QMEAN4 score (33) was chosen. Images were generated with PV, a Java Script Protein Viewer (http://dx.doi.org/10.5281 /zenodo.12620), and VMD 1.9.2 (65) .
Expression of EsLBP1 in insect cells.
The complete open reading frame of EsLBP1 was amplified from E. scolopes cDNA using primers LBP1pBAC3F (5=ATACACCATGGTAATGTCTTGCCCCACTCAA 3=) and LBP1pBAC3R (5=TATCACTCGAGAATAGATGTAATTGCC AAGTC3=). Two single-nucleotide polymorphism (SNPs) resulting in amino acid substitutions relative to the published EsLBP1 sequence, T253S (a change of T to S at position 253) and A218T, were consistently noted in this cDNA preparation and were included in the expressed recombinant EsLBP1. The PCR product was digested with EcoRI and XhoI and ligated into the plasmid pBAC-3 (EMD Millipore, Billerica, MA), adding a leader peptide and His 6 tag, and sequenced. The construct was transfected into and expressed from Sf9 insect cells by Kinnakeet Biotechnology (Midlothian, VA). Conditioned medium from these cells was blotted with anti-tetra-His antibodies (Qiagen), by which means the concentration of EsLBP1 in the undiluted medium was estimated at 2 M. Control medium including His-tagged E. coli ␤-glucuronidase was prepared from cells transfected with the BacMagic3 transfection control plasmid (EMD Millipore).
Preparation of MAMPs. [ 3 H]LOS (5,000 cpm/ng LOS) and [ 14 C]LOS (6 cpm/ng LOS) were extracted and purified from metabolically labeled Neisseria meningitidis and used as aggregates of purified LOS as described previously (66) . The [ 14 C]LOS was used as unlabeled LOS in competition experiments with [ 3 H]LOS (Fig. 2B ). Metabolic labeling with radiolabeled acetate yielded equivalent radiolabeling of all LOS molecules (67) . Unlabeled lipopolysaccharide and lipid A from wild-type V. fischeri, F. tularensis, and N. meningitidis were prepared by the water-phenol method (68) ; diphosporyl E. coli lipid A was purchased from Sigma Aldrich (St. Louis, MO). LPS and LPS derivative stock solutions were sonicated before use as previously described (52); preparations used in animal experiments were initially solubilized at 1 mg/ml in 10-mM PIPES [piperazine-N,N=-bis(2-ethanesulfonic acid)] buffer, pH 6.3, before dilution. Unlabeled TCT was purified from Bordetella pertussis (69); endotoxin contamination was undetectable as assayed with Pyrochrome chromogenic reagent (As-sociates of Cape Cod, East Falmouth, MA). To prepare [ 3 H]TCT, peptidoglycan of N. gonorrhoeae strain kh619 (MS11 ldcA) was metabolically labeled using [6-3 H]-glucosamine (70) and sacculi were purified as described previously (71) . [ 3 H]TCT was produced by digestion of sacculi with gonococcal LtgD, and TCT was purified by reversed-phase highperformance liquid chromatography (HPLC) (71) .
EsLBP1-endotoxin, TCT, and LOS:CD14 complex binding assays. Conditioned medium containing EsLBP1 was used in parallel with equal volumes of control (␤-glucuronidase-containing) conditioned medium ( Fig. 2A and B) or diluted with control conditioned medium (Fig. 2D) to permit the testing of a range of EsLBP1 concentrations. Medium containing EsLBP1 or control medium was mixed with a 3 H-radiolabeled N. meningitidis MAMP, either 5,000 cpm of LOS ( Fig. 2A) or LOS complexed with human CD14 (13) (Fig. 2C) , or 1,000 cpm TCT (Fig. 2D) , along with 0.1% human serum albumin in Dulbecco's phosphate-buffered saline (PBSA) in 0.2-ml reaction mixture volumes and incubated for 30 min at 27°C. Ten microliters of Ni 2ϩ -agarose resin was added, the reaction mixtures were brought to 0.5 ml total with PBSA, and the reaction mixtures were incubated on a rotating wheel for an additional 30 min. The beads were pelleted by gentle centrifugation for 1 min and washed twice with PBSA for 5 min each. Recovery of radiolabeled material in each of the recovered fractions was measured by liquid scintillation spectroscopy. Cocapture of radiolabeled material was calculated as the percentage of the total recovered radioactive material present in beads. For competition experiments (Fig. 2B) , unlabeled LOS/LPS was preincubated with 0.33 nM EsLBP1 for 30 min at 27°C before the addition of 3 H-LOS and incubation and cocapture as described above.
Assay for bactericidal activity of proteins. Cultures of E. coli strain PL2 were grown in tryptic soy broth (TSB) at 37°C to mid-log phase and then diluted 100-fold in TSB with no recombinant protein or 30 nM of one of the following: hBPI-21 (N-terminal fragment of human BPI), hLBP (human LBP) (both from Xoma, Berkeley, CA), or EsLBP1. Cultures were incubated for a further 60 min at 37°C. Aliquots of each culture were diluted 1:6,250, and 10-l amounts were plated in triplicate on tryptic soy agar and incubated overnight at 37°C, and then CFU were counted.
General procedures for animal experiments. Adult E. scolopes animals were collected from the sand flats of O'ahu, HI, and transported and maintained as described in previous publications (72) ; experiments used newly hatched juveniles in artificial seawater collected from the table on which they hatched. Symbiotic animals were exposed to~5,000 CFU/ml of V. fischeri strain ES114 (73); aposymbiotic animals were not. Symbiosis was verified with luminescence using a TD-20/20 luminometer (Turner Designs, Sunnydale, CA). In MAMP treatment experiments, lipid A was used at 10 ng/ml and TCT at 1 M.
qRT-PCR. We stabilized light organ tissues, extracted RNA, prepared cDNA, and conducted quantitative reverse transcriptase PCR (qRT-PCR) experiments in accordance with MIQE guidelines (74), as described previously (75) , except that qRT-PCR used the gene-specific primers given in Table S1 in the supplemental material and the protocol used was 3 min at 94°C and 40 cycles of 15 s at 94°C, 20 s at 59°C, 20 s at 68°C. We used the comparative quantification cycle (⌬⌬Cq) method to determine expression levels (76) . eslbp1 levels were normalized to the mean levels of control transcripts for the 40S ribosomal subunit and serine hydroxymethyltransferase (HMT).
HCR-FISH. Hybridization chain reaction-fluorescent in situ hybridization (HCR-FISH) was used to visualize transcripts of E. scolopes and V. fischeri genes and was performed according to established protocols (77) . All animals examined were collected at 24 h after exposure to V. fischeri strain ES114. The E. scolopes transcripts probed were those of eslbp1 and hsp90, used as a counterstain for E. scolopes tissue. 16S ribosomal subunit transcripts were probed to counterstain for V. fischeri. Probe sequences are given in Table S2 in the supplemental material.
Immunocytochemistry. Immunocytochemistry for EsLBP1 in 18-h postinoculation hatchlings was performed with chicken anti-EsLBP1 antibody and viewed with an LSM510 laser-scanning confocal microscope (Zeiss, Thornwood, NY) as described previously (31) , except that the primary antibody incubation was reduced to 7 days. The fluorophores included goat anti-chicken fluorescein isothiocyanate (FITC) antibody (for EsLBP1), rhodamine-phalloidin (actin cytoskeleton), and TOTO-3 (DNA).
Statistics. For experiments with quantitative comparisons, with the sole exception of comparison of CFU levels (Fig. 3) , data were log transformed to provide for normality prior to statistical analysis. In the time course experiment, the highest eslbp1 level from each treatment was removed as an outlier (Fig. 4A) . Comparisons between treatments were made with analysis of variance (ANOVA) (repeated measures ANOVA for CFU), followed by post hoc pairwise comparisons with Tukey multiple comparisons of means.
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